Article
The IDH paradox: Meta-analysis of alkylating chemotherapy in IDH-wild type and -mutant lower grade gliomas.
Neuro-oncology - 3 Oct 2024
Kinslow Connor J, Roy Soumyajit, Iwamoto Fabio M, Brown Paul D, DeStephano David M, Canoll Peter D, Qureshi Summer S, Gallito Matthew, Sisti Michael B, Bruce Jeffrey N, Horowitz David P, Kachnic Lisa A, Neugut Alfred I, Yu James B, Mehta Minesh P, Cheng Simon K, Wang Tony J C
Abstract excerpt
BACKGROUND: IDH-wild type (-wt) status is a prerequisite for the diagnosis of glioblastoma (GBM); however, IDH-wt gliomas with low-grade or anaplastic morphology have historically been excluded from GBM trials and may represent a distinct prognostic entity. While alkylating agent chemotherapy improves overall survival (OS) and progression-free survival (PFS) for IDH-wt GBM and also IDH-mutant gliomas,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.